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he formation of stem cell–derived tumors (teratomas)
is observed when engrafting undifferentiated em-
bryonic stem (ES) cells, embryoid body–derived
cells (EBCs), or mammalian embryos and is a signiﬁcant
obstacle to stem cell therapy. We show that in tumors
formed after engraftment of EBCs into mouse brain, ex-
pression of the pluripotency marker Oct-4 colocalized
with that of prostate apoptosis response-4 (PAR-4), a
protein mediating ceramide-induced apoptosis during
neural differentiation of ES cells. We tested the ability of
the novel ceramide analogue N-oleoyl serinol (S18) to
eliminate mouse and human Oct-4(
 
 
 
)/PAR-4(
 
 
 
) cells
T
 
and to increase the proportion of nestin(
 
 
 
) neuropro-
genitors in EBC-derived cell cultures and grafts. S18-
treated EBCs persisted in the hippocampal area and
showed neuronal lineage differentiation as indicated by
the expression of 
 
 
 
-tubulin III. However, untreated cells
formed numerous teratomas that contained derivatives of
endoderm, mesoderm, and ectoderm. Our results show
for the ﬁrst time that ceramide-induced apoptosis elimi-
nates residual, pluripotent EBCs, prevents teratoma for-
mation, and enriches the EBCs for cells that undergo
neural differentiation after transplantation.
 
Introduction
 
Pluripotent embryonic stem (ES) cells can be differentiated in
vitro to form a wide array of cell types including germ cells and
a variety of somatic cells including neurons (Deacon et al.,
1998; Brustle et al., 1999; Reubinoff et al., 2001; Rossant, 2001;
Bjorklund et al., 2002; Gottlieb, 2002; Barberi et al., 2003;
Carpenter et al., 2003; Hubner et al., 2003). However, grafts of
stem cells derived from ES cells differentiated via embryoid
bodies (EBs) can be contaminated with residual pluripotent cell
types leading to the formation of teratomas in the host (Bjorklund
et al., 2002; Barberi et al., 2003; Erdo et al., 2003). It is only
poorly understood which extra- or intracellular signals deter-
mine the lineage specification of differentiating stem cells or
maintain their pluripotency, in particular in the host tissue after
transplantation. In the mouse, teratomas or teratocarcinomas can
be experimentally induced by transplanting early stage embryos
to ectopic sites (Martin, 1980). Similarly, in transplants of cells
derived from ES cells, the formation of teratomas appears to
correlate with the degree to which the cells are differentiated
and enriched in cell culture before grafting (Deacon et al., 1998;
Bjorklund et al., 2002). The loss of teratoma forming potential is
probably due to the loss of pluripotent cells that express Oct-4
(Pou5f1), an octamer-type transcription factor and a marker pro-
tein for undifferentiated, pluripotent stem cells that has also
been found to be overexpressed in a variety of cancers (Monk
and Holding, 2001; Pesce and Scholer, 2001; Brickman and
Burdon, 2002; D’Amour and Gage, 2003). During in vitro neural
differentiation of ES cells, the expression of Oct-4 is terminated
and followed by up-regulation of nestin, an intermediate fila-
ment protein and marker for committed neural precursor cells
(Cai et al., 2002; Pevny and Rao, 2003). This observation
implies that in teratomas, the expression of Oct-4 may persist in
a portion of the transplanted cells, which most likely results in
their hyperproliferation and tumor formation instead of com-
mitment to further neural differentiation. It is important to develop
a greater understanding of how pluripotent cell types can persist
in ES-derived cell grafts and to explore additional or alternative
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approaches to remove pluripotent cells from ES-derived cells.
One attractive approach is to exploit the differential sensitivity
to apoptosis inducers to rid neuroprogenitors (NPs) of rogue
cells that are likely to form teratomas. However, there is only
little known about the characteristics of tumorigenic stem cells,
and there are no methods established to actively eliminate these
cells from the population of committed progenitor cells and dif-
ferentiated cell types that can be used for safe stem cell therapy.
Most recently, we have found that the expression of pros-
tate apoptosis response-4 (PAR-4), an endogenous inhibitor
protein of atypical PKC
 
 
 
, mediates ceramide or ceramide ana-
logue-induced apoptosis in proliferating EB-derived stem cells
(Bieberich et al., 2001, 2003). The apoptotic response is spe-
cific for PAR-4(
 
 
 
) cells because proliferating cells with low
expression of PAR-4 are less sensitive to ceramide or ceramide
analogue-induced apoptosis (Bieberich et al., 2003). We also
observed that in cell culture, ceramide/PAR-4–induced apopto-
sis is predominant during or before early neural progenitor for-
mation from mouse EB-derived cells (EBCs; Bieberich et al.,
2003). However, the majority of EBC-derived nestin(
 
 
 
) cells
do not express PAR-4 and are thus resistant to ceramide-induc-
ible apoptosis. From these observations, we conclude that there
is a portion of proliferating, Oct-4(
 
 
 
)/PAR-4(
 
 
 
) stem cells in
EBCs that can be eliminated due to apoptosis by incubation
with ceramide or ceramide analogues. In the current work, we
tested the ability of S18 (N-oleoyl serinol), a novel ceramide
analogue that has recently been synthesized in our laboratory to
induce apoptosis in mouse and human EBCs (Bieberich et al.,
2000, 2002). We used multilineage teratoma formation in neo-
natal mouse brain as an assay to measure the level of pluripo-
tent cells in mouse EBCs with or without incubation with S18
before engraftment into mouse brain. Our results show for the
first time that Oct-4(
 
 
 
)/PAR-4(
 
 
 
) stem cells can be elimi-
nated and nestin(
 
 
 
) neural precursors can be enriched in EBCs
by incubation with novel ceramide analogues and that this en-
richment prevents teratoma formation and promotes neural dif-
ferentiation after engraftment into mouse brain.
 
Results
 
S18-induced formation of a PAR-4–PKC
 
 
 
 
complex and inhibition of PKC
 
 
 
 triggers 
apoptosis in EBCs
 
We have reported that apoptosis of EBCs is induced by simulta-
neous elevation of endogenous ceramide and PAR-4, a protein
that binds and inhibits atypical PKC
 
 
 
 and a variety of other pro-
teins (Sells et al., 1994, 1997; Diaz-Meco et al., 1996; Guo et
al., 1998; Bieberich et al., 2003; Gurumurthy and Rangnekar,
2004). We have also shown that overexpression or antisense
knockdown of PAR-4 increases or reduces the sensitivity of dif-
ferentiating ES cells toward ceramide or ceramide analogue-
inducible apoptosis, respectively (Bieberich et al., 2003). How-
ever, it remained to be investigated at which differentiation
stage and how ceramide-inducible apoptosis is regulated by
PAR-4–mediated inhibition of PKC
 
 
 
. It has been reported that
C2-ceramide induces formation of a protein complex between
PKC
 
 
 
 and PAR-4 in PC12 cells before apoptosis (Wang et al.,
1999). A potential S18-induced formation of a PKC
 
 
 
–PAR-4
complex in EBCs was tested using coimmunoprecipitation as-
says with protein from cells that were treated with or without
S18. Fig. 1 A shows that no precipitated protein was found
when the primary antibody was omitted, which verified the
specificity of the immunoprecipitation reaction. If the same pri-
mary antibody was used for immunoprecipitation and immuno-
blotting, the signal was not altered by prior incubation of the
stem cells with S18. This result indicated that the amount of im-
munoprecipitated protein was not affected by S18. However,
treatment with S18 was required to coimmunoprecipitate PKC
 
 
 
or PAR-4 using primary antibodies against PAR-4 or PKC
 
 
 
, re-
spectively. This observation showed that S18 induced formation
of a complex between PKC
 
 
 
 and its inhibitor protein PAR-4.
The amount of coimmunoprecipitated PKC
 
 
 
 appeared to
be smaller than the total amount of PKC
 
 
 
, suggesting that only
a portion of the complex was immunoprecipitated using the
PAR-4–specific antibody. Alternatively, S18-induced binding
of a portion of PKC
 
 
 
 to PAR-4 may be sufficient to induce
apoptosis in EBCs. To test the effect of PKC
 
 
 
 inhibition on the
induction of apoptosis, EBCs were incubated with a pseudosub-
strate inhibitor peptide of PKC
 
 
 
 (PZI). This peptide has been
shown to specifically inhibit the activity of PKC
 
 
 
 or its activa-
tion in a variety of cell systems (Gailly et al., 1997; Laudanna et
al., 1998; Muscella et al., 2003). Fig. 1 B shows that PZI in-
duced apoptosis at equivalent levels regardless of the time pe-
riod after replating of dissociated EBs. This result suggests that
inhibition of PKC
 
 
 
 is sufficient to induce apoptosis in EBCs at
various differentiation stages. However, when EBCs were incu-
bated with S18 and other ceramide analogues (C2-ceramide or
C16-ceramide), the degree of apoptosis dropped by 
 
 
 
70%
within 48 h after replating of cells from dissociated EBs (Fig. 1
B). This effect was observed for spontaneous (endogenously
regulated) as well as ceramide analogue-inducible apoptosis.
Fig. 1 (C and D) shows that the gene and protein expression
level of PAR-4 was highest at 24 h after dissociation (NP2-
stage) and dropped by 80% within the first 48 h thereafter, con-
comitant with the decline of the degree of spontaneous or cer-
amide analogue-induced apoptosis. These results suggest that
ceramide analogue-induced formation of an inhibitory PAR-4–
PKC
 
 
 
 complex and thus the degree of apoptosis in differentiat-
ing ES cells is dependent on the expression level of PAR-4.
Fig. 1 C shows the gene expression level of PAR-4, nes-
tin, and Oct-4, a transcription factor required for the mainte-
nance of undifferentiated and pluripotent ES cells. Our results
show that at the late EB and early NP stage Oct-4, PAR-4, and
nestin were coexpressed in differentiating ES cultures, indicat-
ing that pluripotent (Oct-4(
 
 
 
)) cells and NPs (nestin(
 
 
 
)) coex-
isted at these differentiation stages. Coexistence of pluripotent
stem cells and NPs was thus concomitant with the highest de-
gree of S18-inducible apoptosis in EBs and EBCs.
 
Ceramide-induced apoptosis diminishes 
Oct-4(
 
 
 
)/PAR-4(
 
 
 
) mouse and human 
stem cells in EBs
 
Recently, we have reported that ceramide or S18 rapidly in-
duces apoptosis in proliferating EBCs that express a high level 
REDUCTION OF TERATOMA FORMATION WITH CERAMIDE ANALOGUES • BIEBERICH ET AL.
 
725
 
of PAR-4, but little or no nestin (Bieberich et al., 2003). To de-
termine whether or not ceramide-sensitive PAR-4(
 
 
 
) cells are
pluripotent EBCs, we analyzed the expression of PAR-4 and
Oct-4 by immunofluorescence microscopy. Fig. 2 A shows the
effect of S18 on mouse EBs resulting in apoptosis and, eventu-
ally, loss of cells in the center of the EBs, whereas cells imme-
diately surrounding the EBs were resistant toward S18. The
apoptotic cells were identified as Oct-4 and PAR-4 double pos-
itive, indicating that residual Oct-4(
 
 
 
)/PAR-4(
 
 
 
) cells within
the EBs maintained their sensitivity toward ceramide or cer-
amide analogues (Fig. 2 B). A similar subpopulation of apop-
totic cells was found when EBs from human ES cells were in-
cubated with S18 (Fig. 2 C). Confocal immunofluorescence
microscopy confirmed that TUNEL(
 
 
 
) human cells within the
EBs also stained for PAR-4 (Fig. 2 D, arrow 1) or Oct-4 and
PAR-4 (Fig. 2 D, arrow 2).
To quantify the effect of ceramide-induced apoptosis on
EBCs, mouse EBs cultivated in serum-free medium were incu-
bated for 24 h with 80 
 
 
 
M of S18 or 2 
 
 
 
M of myriocin, a cer-
amide biosynthesis inhibitor, before magnetic-activated cell
sorting (MACS) for Annexin V (
 
 
 
) EBCs and fluorochrome
inhibitor of caspase (FLICA) tagging of activated caspases.
Annexin V–MACS separated cells that were in the initial
phase of apoptosis induction, whereas FLICA staining identi-
fied cells that executed apoptosis by caspase activation. Table
I and Fig. 3 show the results of Oct-4 and PAR-4 staining in
MACS-sorted Annexin (
 
 
 
) or (
 
 
 
) EBCs. With untreated con-
trol cells, the Annexin V(
 
 
 
) and (
 
 
 
) fractions contained
PAR-4(
 
 
 
) and Oct-4(
 
 
 
) cells (Fig. 3 A), whereas with S18-
treated cells, only the Annexin V(
 
 
 
) fraction contained PAR-
4(
 
 
 
) and Oct-4(
 
 
 
) cells (Fig. 3 B). Almost all of the PAR-
4(
 
 
 
) cells were also Oct-4(
 
 
 
) indicating that S18-induced
apoptosis could efficiently eliminate Oct-4(
 
 
 
) cells from
EBCs (Table I and Fig. 3 B). In cells not treated with S18, in-
hibition of endogenous ceramide biosynthesis with myriocin
prevented apoptosis in PAR-4(
 
 
 
) cells, which implied that
Oct-4(
 
 
 
) cells were preserved as well (Table I). FLICA stain-
ing revealed that S18 increased apoptosis from 25% in un-
treated cells to 55% in S18-treated cells, whereas 
 
 
 
10% of the
myriocin-treated cells were FLICA positive.
Within the two MACS fractions of untreated or S18-
treated EBCs, more than 80% of the FLICA(
 
 
 
) cells were
found in the Annexin V(
 
 
 
) fraction, which confirmed the ex-
ecution of apoptosis by caspase activation and verified the
Figure 1. S18-induced formation of a PAR-4–
PKC  complex and PAR-4 dependent apoptosis.
(A) EBCs (NP2 stage) were incubated over-
night with or without 80  M of S18. Cellular
protein was solubilized and antigen–antibody
complexes were immunoprecipitated, followed
by SDS-PAGE and immunoblotting. (B) EBCs
(NP2, 3, and 4 stages) were incubated with
various ceramide-like apoptosis inducers and
the degree of apoptosis was quantified by
counting of cells with activated caspases
(FLICA assay). All results were from three inde-
pendent experiments showing average values
and SEMs of cell counts from five areas with
more than 100 cells. Treated cells show statis-
tically significant differences to nontreated
control cells as evaluated by ANOVA. C2,
N-acetyl sphingosine (30  M); C16, N-palmi-
toyl sphingosine (2  M, incubated in solution
with dodecanol as described in Bieberich et
al., 2003); PZI, myristoylated PKC  pseudo-
substrate inhibitor peptide (30  M). Open
bars, NP2 stage (24 h after replating of EBCs);
gray bars, NP3 stage (48 h after replating of
EBCs); black bars, NP4 stage (72 h after re-
plating of EBCs). (C and D) The level of Oct-4,
PAR-4, and nestin gene expression was deter-
mined by RT-PCR during differentiation of EBCs
from mouse. The expression level of PAR-4
protein was determined by immunoblotting
using a mouse monoclonal anti–PAR-4 anti-
body. EB6, 7, and 8 are EBs 48, 72, and 96 h
after attachment of suspension EBs; NP stages
as in B. 
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high quality of separation by Annexin V–based MACS (Fig.
3, A and B). However, a small fraction of the Annexin V(
 
 
 
)
cells from untreated EBs were FLICA(
 
 
 
) and recovered from
the induction of apoptosis as indicated by their spread out
morphology and noncondensed nuclei (Table I and Fig. 3 A,
cells are labeled with asterisk). This population of Oct-4(
 
 
 
)/
PAR-4(
 
 
 
) cells was almost completely eliminated by incuba-
tion with S18 as indicated by FLICA staining of cells in the
Annexin V(
 
 
 
) MACS fraction (Table I and Fig. 3 B). In sum-
mary, our results show that the majority of Oct-4(
 
 
 
) cells
also expressed PAR-4. Ceramide-induced apoptosis eliminated
Oct-4(
 
 
 
)/PAR-4(
 
 
 
) cells regardless of whether ceramide
was elevated by endogenous biosynthesis or was added to the
medium. If apoptosis was endogenously induced, a consider-
Figure 2. Treatment with ceramide ana-
logues eliminates Oct-4( )/PAR-4( ) cells in
EBs derived from mouse or human ES cells.
(A) Mouse EBs were incubated for 24 (middle)
or 48 h (right) with 80  M of S18 showing
ongoing cell death in the peripheral and cen-
tral region of the EB. (B) The center of S18-
treated mouse EBs shows intensive costaining
of Annexin V (FITC, green)–, PAR-4 (Cy3,
red)–, and Oct-4 (Cy5, blue)–positive cells.
(C and D) S18-treated human EBs were
stained for apoptotic cells using TUNEL assays
(FITC, green) and confocal immunofluores-
cence microscopy was used to detect PAR-4
(Cy3, red)– and Oct-4 (Cy5, pink)–positive
cells. Arrows show apoptotic Oct-4( )/PAR-
4( ) (arrowhead 2) or Oct-4( )/PAR-4( )
(arrowhead 1) cells.
 
Table I. 
 
Expression of PAR-4 and Oct-4, and apoptosis in EBCs sorted by Annexin V–MACS
Annexin V negative Annexin V positive
FLICA PAR-4 Oct-4 P/O F/P/O FLICA PAR-4 Oct-4 P/O F/P/O
 
 
 
S18 6 
 
 
 
 1 14 
 
 
 
 38  
 
 
 
 18  
 
 
 
 15  
 
 
 
 2 18 
 
 
 
 2 37 
 
 
 
 2 26 
 
 
 
 2 25 
 
 
 
 1 17 
 
 
 
 1
 
 
 
S18 3 
 
 
 
 25  
 
 
 
 1
 
 
 
2
 
 
 
2
 
 
 
2 48 
 
 
 
 2 52 
 
 
 
 3 33 
 
  2 30   1 28   2
 Myr 2   1  40   3 27   2 26   2  24     18    25    15    13    1
Mouse EBs were treated as described in Fig. 2. Numbers show portion of cells with particular feature as percentage of total cells in both MACS fractions combined.
Average values and SEMs were calculated from cell counts in four independent experiments with more than 100 cells in five areas used for counting. Statistical
significant differences were evaluated by ANOVA. F, FLICA( ) cells; P, PAR-4( ) cells; O, Oct-4( ) cells.REDUCTION OF TERATOMA FORMATION WITH CERAMIDE ANALOGUES • BIEBERICH ET AL. 727
able fraction of the Oct-4( )/PAR-4( ) cells recovered from
the initial phase of apoptosis induction, but was eliminated by
incubation with S18.
Ceramide-induced apoptosis enriches 
nestin-positive neural progenitors 
in EBCs
We defined the population of S18-sensitive and -insensitive
cells using immunocytochemistry for the expression of PAR-4,
Oct-4, and nestin in attached EBs. Fig. 3 C shows that in un-
treated EBs, Oct-4( )/PAR-4( ) cells are mostly confined to
the center of the EBs, which is consistent with the result shown
in Fig. 2 B. Nestin staining was found in cells that immediately
surrounded the EB and some apparently migrating cells outside
of the EBs. Consistent with our previous study (Bieberich et
al., 2003), the small number of cells that coexpressed PAR-4
and nestin showed asymmetric subcellular distribution of the
two proteins (Fig. 3 C, arrow). TUNEL and Annexin V staining
in Fig. 3 D shows that S18 induced apoptosis selectively in nes-
tin( ) cells of the central EB and in single, peripheral nes-
tin( ) cells, but not in nestin( ) cells that immediately sur-
rounded the central EB. The resistance of cells that highly
express filamentous nestin toward ceramide-inducible apopto-
sis was also found with human EBs (unpublished data), sug-
gesting that ceramide induces apoptosis in a similar population
of pluripotent Oct-4( )/PAR-4( ) cells derived from mouse
or human EBs.
To monitor further neural differentiation of S18-treated
EBCs, we determined the expression of Oct-4, PAR-4, and nes-
tin 24 h after dissociation and replating of untreated or S18-
treated EBs. Table II and Fig. 4 A show that S18 reduced the
number of Oct-4( )/PAR-4( ) by 70%, whereas the number
of nestin( ) cells was not diminished. On the contrary, the por-
tion of nestin( ) cells from S18-treated EBs showed the same
proliferation rate as obtained with untreated cells and even in-
creased by twofold (Table II), most likely due to their resis-
tance to S18-inducible apoptosis (Bieberich et al., 2003). In
contrast to untreated cells, almost all of the Oct-4( )/PAR-
4( ) cells from S18-treated EBs were FLICA( ), indicating
that they were actively undergoing apoptosis and demonstrat-
ing that S18 eliminated residual Oct-4( ) positive cells from
the EBCs (Table II). These results were consistent with those
from MACS sorting (Table I). They also verified that S18 treat-
ment spared the S18-resistant, nestin( ) cell population while
inducing apoptosis in nearly all of the Oct-4( ) population of
EBCs (Table II).
Figure 3. S18-induced apoptosis eliminates
Oct-4( )/PAR-4( ) pluripotent stem cells and
enriches for nestin( ) NPs. (A and B) MACS
sorting of apoptotic EBCs. Mouse EBCs from
untreated (A) or S18-treated (80  M; B) EBs
were incubated with Annexin V–conjugated
magnetic beads and fractionated using
MACS. Flow through cells (Annexin V( )) and
retained cells (Annexin V( )) were precipi-
tated on lysine-coated coverslips, incubated with
FLICA substrate, and after fixation, immuno-
stained for the expression of PAR-4 (Cy3, red)
and Oct-4 (Cy5, green). FLICA-negative and
-positive cells are labeled with ( ) or ( ),
respectively. Arrows indicate Oct-4( )/PAR-
4( ) cells. Asterisks label cells in the Annexin
V( ) fraction that recovered from the initial
phase of apoptosis. (C) Radial expansion and
neural differentiation of mouse EBs stained for
the expression of nestin (Cy3, red), PAR-4
(Cy2, green), and Oct-4 (Cy5, blue). Arrow
points at cell showing coexpression and sub-
cellular segregation of nestin and PAR-4. (D)
Mouse EBs incubated overnight with 80  M
of S18 were stained for apoptotic cells
(TUNEL or Annexin V, FITC, green) and nestin
(Cy3, red).JCB • VOLUME 167 • NUMBER 4 • 2004 728
The specific enrichment of nestin( ) EBCs by S18 treat-
ment was also shown by immunoblots indicating that the level
of PAR-4 and Oct-4 protein was greatly reduced, whereas that
of nestin was increased in the S18-treated cell population rela-
tive to the untreated cultures (Fig. 4 B). This observation was
consistent with the diminished gene expression for Oct-4 and
Tert, another marker for pluripotent stem cells, after S18 treat-
ment (Fig. 4 C). The gene expression for Sox-2 (marker for
pluripotent stem cells and NPs), Sox-1 (NP marker), and NF-
66 (an early neuronal marker; Kure and Brown, 1995; Chan et
al., 1997; Graham et al., 2003) was not decreased or only re-
duced to a limited extent, indicating that the ratio of neuronal
precursor cells to pluripotent stem cells was enhanced by treat-
ment with the ceramide analogue, which is consistent with the
data shown in Table II (Bylund et al., 2003). The amount of the
antiapoptotic protein Bcl-2 was increased in cells derived from
S18-treated EBCs, suggesting that the subpopulation of nes-
tin( ) cells that survived S18 treatment expressed high levels
of Bcl-2, which may have protected them against S18-induc-
ible apoptosis (Fig. 4 B).
The effect of S18 treatment on the neuronal differentiation
of EBC-derived NPs was determined by immunofluorescence
staining for the intermediate filament protein NF-66 and the neu-
ronal marker MAP-2 or glial marker GFAP (Chan et al., 1997;
Figure 4. Nestin( ) NPs enriched from S18-
treated EBs undergo rapid neuronal differenti-
ation. (A) Mouse EBs were incubated with or
without 80  M of S18 and then expanded
for 24 h to induce differentiation into NPs.
Expanded NPs were stained for nestin (Cy3,
red), PAR-4 (Cy2, green), and Oct-4 (Cy5,
pink). Arrow indicates Oct-4( )/PAR-4( )
cell. (B and C) Protein and mRNA was iso-
lated from expanded NPs and then used for
immunoblotting (B) or RT-PCR (C) for the ex-
pression of various genes and proteins (nestin,
Oct-4, PAR-4, Sox-2, Sox-1, Tert, Bcl-2, and
NF-66), respectively. (D) EBCs 72 h after expan-
sion of EBs were stained for nestin (Cy3, red),
NF-66 (Cy2, green), or GFAP (Cy5, pink). (E)
EBCs 72 h after expansion of EBs were
stained for NF-66 (Cy2, green) and DNA
(Hoechst, blue). Arrows indicate cells with
extensive formation of processes that stain for
filamentous NF-66.
Table II. Expression of PAR-4, Oct-4, and nestin, and apoptosis in 
expanded EBCs
Nestin FLICA PAR-4 Oct-4 PAR/Oct F/P/O
 S18 33   3 27   2 55   2 31   2 29   2 12   1
 S18 64   3 12   1 13   1 10   19    18    1
Mouse EBs were treated and recultivated as described in Fig. 4. Numbers show
portion of cells with particular feature as a percentage of total cells. For statistical
evaluation see legend for Table I.REDUCTION OF TERATOMA FORMATION WITH CERAMIDE ANALOGUES • BIEBERICH ET AL. 729
Bieberich et al., 2003). Fig. 4 D shows that NF-66 was very
early expressed during NP differentiation, whereas GFAP was
not expressed. In terminally differentiated cells, MAP-2( ) neu-
rons and GFAP( ) glial cells were equally formed, which was
not altered by prior incubation of EBs with S18 (unpublished
data). This result indicates that S18 did not impair terminal dif-
ferentiation of EBCs by eliminating Oct-4( )/PAR-4( ) cells.
On the contrary, in areas with comparable cell density, S18 treat-
ment of EBs resulted in the early assembly of numerous NF-
66( ) processes 48 h after expansion of the EBC whereas only
few processes were seen without treatment (Fig. 4 E). The accel-
erated differentiation to NF-66( ) early neurons may have re-
sulted from the increased population of nestin( ) NPs due to
S18 treatment of EBs before expansion or may have been due to
ceramide analogue-promoted neuronal differentiation.
S18-treated EBCs are less likely to form 
teratomas and undergo neuronal 
differentiation after transplantation into 
mouse brain
Stem cells derived from dissociated EBs are the earliest source
for neural precursor cells and have been tested as a source of
cells for stem cell transplantation (Deacon et al., 1998; Bjorklund
et al., 2002). However, previous papers reported that in some of
the animals, transplantation of EBCs resulted in the formation of
stem cell–derived tumors (teratomas; Bjorklund et al., 2002; Bar-
beri et al., 2003; Erdo et al., 2003). Because S18 treatment re-
duced the proportion of proliferating, pluripotent Oct-4( )/PAR-
4( ) cells in EBs, we hypothesized that S18-treated EBCs would
be less likely to form teratomas in vivo. The EBCs from two ES
cell lines (ES-J1 and ROSA-26) were labeled with Vybrant CM
diI, a red fluorescent, nontoxic, permanent dye for tracking of the
injected cells (Iwaguro et al., 2002). The injected cells were also
identified by additional methods based on in situ hybridization to
a fluorescent DNA probe for detection of the Y-chromosome in
the male donor EBCs (Y-mapping), and by immunofluorescence
staining for  -galactosidase in ROSA-26 cells (Zambrowicz et
al., 1997). In each experiment, we monitored survival and neural
differentiation of the EBCs by further cultivating an aliquot of
the cell suspension used for injection in culture.
In preliminary studies, we found that intrastriatal injec-
tion of untreated EBCs into postnatal day 10 mice gave rise to
5–7 tumors throughout the brain after 6 wk in 12 out of 15 ani-
mals (Table III). Fig. 5 A shows a massive tumor that emerged
on the surface of the right hemisphere at the injection site of
the untreated EBCs. Immunohistochemistry using antibodies
against  -fetoprotein, desmin, vimentin, and GFAP confirmed
that the grafted EBCs had formed teratomas containing endo-
dermal, mesodermal, and ectodermal tissues (Fig. 5 B; Vance
et al., 1988; Sangruchi and Sobel, 1989). Within the teratomas,
nestin expressing cells did not express PAR-4 as we would pre-
dict from previous studies of in vitro ES cell differentiation
(Bieberich et al., 2003; Fig. 5 C). However, PAR-4( )/nes-
tin( ) cells in the center of nestin( ) cell clusters expressed
Oct-4 (Fig. 5 D). These results indicated that EBC-derived ter-
atomas maintained a subpopulation of pluripotent, Oct-4( )/
PAR-4( )/nestin( ) stem cells.
We tested if treatment of EBs with S18 eliminated the
residual pluripotent Oct-4( )/PAR-4( ) stem cells and pre-
vented teratoma formation from EBC-derived transplants. Ta-
ble III shows that the majority of untreated ROSA-26–derived
EBCs formed invasive striatal/cortical and noninvasive ven-
tricular,   -galactosidase–positive tumors (Fig. 6 A). We la-
beled untreated EBCs with Vybrant CM diI (red) and S18-
treated EBCs with Vybrant diO (green) and injected a mixed
population of these cells into the striatum of the same mouse.
Untreated, diI-labeled stem cells developed ventricular and in-
vasive, striatal and cortical tumors, whereas S18-treated, diO-
labeled cells integrated into the subependymal cell layer (Fig. 6
B and Table III) and ventromedial aspects of the hippocampus.
Fig. 6 C shows that integration of S18-treated cells in ar-
eas below the dentate gyrus was concurrent with immunostain-
ing for nestin, indicating intensive neural precursor formation
from the EBC-derived transplants. Costaining of nestin( )
neural precursors for Vybrant CM-diI,  -galactosidase, and the
Y-chromosome ruled out that nestin staining was contributed
by endogenous NPs, which is consistent with sparse staining of
endogenous cells as reported previously (Fig. 6, C and D; Wen
et al., 2002). The degree of neuronal differentiation in the nes-
tin( ) NP layer was determined by staining for  -tubulin III, a
marker for neuronal differentiation (Vance et al., 1988). Fig. 6
E shows widespread staining for  -tubulin III in S18-treated,
Vybrant CM-diI–labeled EBCs used for engraftment. This re-
sult indicates that treatment of EBs with S18 prevented ter-
atoma formation and, at the same time, allowed for neuronal
differentiation after engraftment of EBCs into mouse brain.
Discussion
We have shown that the various cell types in EBs derived from
mouse and human ES cells are differentially sensitive to cer-
amide-inducible apoptosis. This differential sensitivity appears
to be determined by whether or not the cells express the proap-
optotic protein PAR-4. Our previous work had found that
mouse ES cells expressing PAR-4 are rapidly induced to un-
dergo apoptosis by the novel ceramide analogue S18 (Bieber-
ich et al., 2001, 2003). The sensitivity of differentiating ES
cells toward S18-inducible apoptosis was increased or reduced
by overexpression or morpholino antisense-knockdown of
PAR-4, respectively. Using Annexin V–MACS we were now
able to quantify the number of PAR-4( ) EBCs in the Annexin
Table III. Tumor formation from neural transplants of EBCs from 
untreated and S18-treated EBs
Invasive tumors Ventricular tumors
Animals
with tumor
Tumors/animal Animals
with tumor
Tumors/animal
Untreated EBs 10/15 2   1 12/15 5   2
S18-treated EBs 0/15
a 0 3/15
a 2   1
Mouse EBCs were prepared and injected into the striatum of neonatal mice (n  
15) as described in Fig. 5. Tumor formation was analyzed using coronal
vibratome sections.
aStatistically significant differences between untreated and treated cells used for
engraftment as evaluated by t test.JCB • VOLUME 167 • NUMBER 4 • 2004 730
V( ) and ( ) fractions that express the pluripotency marker
Oct-4. We have shown that during mouse and human ES cell
differentiation, a substantial proportion of the apoptotic and
nonapoptotic Oct-4( ) EBCs also express PAR-4. Hence, we
conclude that it is the high expression level of PAR-4 in the
subpopulation of Oct-4( ) EBCs that confers sensitivity to-
ward ceramide and ceramide analogues. This conclusion is also
evident for other rapidly dividing cells whose sensitivity to-
ward S18 is dependent on the expression level of PAR-4 (Bie-
berich et al., 2001, 2002, 2003).
Apoptosis mediated by PAR-4 may involve the regula-
tion of several downstream targets, and inhibition of PKC 
may at least partly explain the effects observed in our paper for
the following reasons: (a) the novel ceramide analogue S18 in-
duces the formation of a protein complex between PAR-4 and
PKC ; (b) inhibition of PKC  using a specific pseudosubstrate
peptide is sufficient to induce apoptosis in EBCs; and (c) S18
eliminates the Oct-4( )/PAR-4( ) cell population, whereas
nestin( )/PAR-4( ) cells survive, proliferate, and differenti-
ate into neural cells. The ceramide analogue-induced elimina-
tion of Oct-4( )/PAR-4( ) mouse and human cells suggests
that a similar subpopulation of pluripotent mouse or human
EBCs is specifically sensitive toward ceramide or ceramide an-
alogues, whereas committed neural precursors are resistant.
Neither the proliferation rate of nestin( )/PAR-4( ) cells nor
the ability of EBCs to undergo neuronal differentiation is di-
minished by the elimination of residual Oct-4( )/PAR-4( )
EBCs. In cell transplantation experiments using EBCs, we
found that teratomas contained residual nonapoptotic Oct-
4( )/PAR-4( ) cells whose specific elimination by S18-
induced apoptosis before grafting prevented teratoma forma-
tion and enhanced integration of the treated cells into neural tissue.
Figure 5. Oct-4( )/PAR-4( ) cells persist in teratomas
from brain transplants of untreated EBCs. (A) Mouse
EBs were incubated with or without 80  M of the
novel ceramide analogue S18 and 100,000 untreated
(left) or 200,000 S18-treated (right) EBCs injected
into the striatum of C57BL6 mice (right hemisphere,
arrow shows injection site). After 6 wk, mice were
killed and teratoma formation was analyzed (some
mice had to be killed earlier to avoid distress to the
animal). (B) The teratoma obtained with untreated
EBCs (left; Fig. 1 A) was vibratome sectioned and the
sections immunostained for the endodermal marker
 -fetoprotein (AFP, Cy2, green), the mesodermal
marker desmin (Cy3, red), the ectodermal marker
vimentin (Cy5, blue, middle), and the neuro-ectodermal
and glial marker GFAP (Cy5, blue, right). (C) Immuno-
histochemistry was also performed for nestin (Cy3,
red) and PAR-4 (Cy2, green). (D) Immunostaining of
nestin (Cy3, red), PAR-4 (Cy2, green), and Oct-4
(Cy5, red) at higher magnification.REDUCTION OF TERATOMA FORMATION WITH CERAMIDE ANALOGUES • BIEBERICH ET AL. 731
From these results, we conclude that treatment of EBs with S18
prevents teratoma formation from residual, pluripotent EBCs in
favor of neural differentiation from enriched neural precursors.
Prevention of teratoma formation resulted from the selec-
tive elimination of Oct-4( )/PAR-4( ) cells that were either
not apoptotic or had recovered from the initial phase of apopto-
sis in untreated EBCs. Cells escaping from death due to re-
versed or interrupted apoptosis (“Zombie cells”) have been
reported previously (Narula et al., 2001). In the case of pluripo-
tent stem cells, they may be a source for unwanted teratoma
formation unless forced to complete programmed cell death.
Selective elimination of Oct-4( )/PAR-4( ) cells is consistent
with the observation that after plating of S18-treated EBCs the
ratio of nestin( ) to Oct-4( ) cells was substantially in-
creased. The surviving S18-treated EBCs underwent rapid dif-
ferentiation to neuronal precursors as shown by nestin,  -tubu-
lin III, and NF-66 staining, in vitro as well as in vivo after
grafting. The S18-treated cells integrated into the subependy-
mal layer and in areas below the dentate gyrus. The intensive
staining for neuronal markers shows early differentiation of
neuronal cells, suggesting that treatment with novel ceramide
analogues not only prevents teratoma formation but also sup-
ports neuronal differentiation. It has been suggested that cer-
amide may be involved in apoptosis and differentiation de-
pending on the context of cell signaling. In particular, the
expression of the antiapoptotic protein Bcl-2 has been found to
channel the ceramide response toward neuronal differentiation,
whereas the expression of PAR-4 favors an apoptotic response
(Diaz-Meco et al., 1996; Zhang et al., 1996; Sells et al., 1997;
Guo et al., 1998; Suzuki and Tsutomi, 1998; Bieberich et al.,
2000, 2003; Chen et al., 2001; Esdar et al., 2001; Luberto et al.,
2002; Liang et al., 2003). These results are consistent with the
observation that the expression of Bcl-2 is elevated in S18-
treated EBCs that survive ceramide-induced apoptosis und un-
dergo further neuronal differentiation.
Several investigators have performed neural cell trans-
plants using mouse or human ES cell–derived cell types (Dea-
con et al., 1998; Brustle et al., 1999; Rossant, 2001; Reubinoff
et al., 2001; Bjorklund et al., 2002; Gottlieb, 2002; Carpenter et
al., 2003; Hubner et al., 2003). In many of these studies terato-
mas were not reported. In these cases, the transplanted cells
were differentiated cell types that had been derived from the
ES cells using lengthy multistep procedures involving repeated
passaging and exposure to growth/differentiation factors or ret-
inoic acid (Brustle et al., 1999; Reubinoff et al., 2001; Gottlieb,
2002; Barberi et al., 2003; Carpenter et al., 2003). An alterna-
tive approach has been reported for generating functional mid-
brain dopaminergic neurons from mouse ES cells by trans-
planting cells derived from EBs after only 4 d of differentiation
in suspension culture. Although these investigators injected
Figure 6. EBCs from untreated EBs form
highly invasive cortical and ventricular tumors,
whereas S18-treated EBCs show enhanced
neuronal differentiation after engraftment.
(A) A tumor developed from Vybrant CM diI-
labeled ROSA-26 EBCs was immunostained
for  -galactosidase (Cy2, green). The arrow
indicates a residual cluster of Vybrant CM diI-
labeled cells. (B) S18-treated or untreated
EBCs were stained with Vybrant CM diI (red,
untreated cells) or Vybrant diO (green, treated
cells), mixed, and injected into the striatum of
neonatal mice. The figure shows settlement
of treated cells in the subependymal layer,
whereas untreated EBCs form a neural tube-like
tumor in the lumen of the right lateral ventricle.
(C) Mouse EBCs derived from S18-treated EBs
were injected into the striatum of neonatal
mice and immunostained for nestin (Cy3, red).
(D) After nestin staining, frozen sections were
FISH-stained for Y-chromosomes (FITC, green).
DNA was counterstained with Hoechst dye
(blue). (E) Mouse EBs were treated with 80
 M of S18, labeled with Vybrant CM diI
(red), and injected into the striatum of neonatal
mice. 6 wk after engraftment, brain sections
were immunostained for  -tubulin III (Cy2,
green). Arrrow shows cluster of Vybrant CM
diI-positive (red) cells that are double-stained
for  -tubulin III (Cy2, cryosectioned, confocal).JCB • VOLUME 167 • NUMBER 4 • 2004 732
many fewer EBCs (1–2   10
3 cells) compared with the number
used in our injections (10
5 cells), teratomas still formed in
 26% (5/19) of the hosts and an additional 15% (3/19) con-
tained graft-derived nonneural cell types (Bjorklund et al.,
2002). Our work suggests that treatment of EBCs with cer-
amide or novel ceramide analogues kills pluripotent cells, en-
riches for neural progenitors, and obliterates the teratoma form-
ing potential of these cells. In future work, we will investigate
the regulatory interdependence of pluripotency (as determined
by Oct-4) and sensitivity toward ceramide-inducible apoptosis
(as determined by PAR-4). We will also graft S18-treated
EBCs into adult mice and investigate if these cells survive and
differentiate in a more hostile environment as present in the
adult brain. Our results suggest that exposure to novel ceramide
analogues may be a useful new method for eliminating pluripo-
tent cell types from differentiating ES cell cultures before
transplantation and, subsequently, enhancing neuronal differ-
entiation for safe stem cell therapy.
Materials and methods
Materials
ES-J1 and feeder fibroblasts were purchased from the ES core facility (A.
Eroglu, Medical College of Georgia, Augusta, GA). ROSA-26 cells were a
gift from P. Soriano (Fred Hutchinson Cancer Research Center, Seattle,
WA). The National Institutes of Health–registered human ES cell line BG01
was obtained from BresaGen and were karyotypic normal. Polyclonal rab-
bit antibody against NF-66 was provided by F.C.A. Chiu (Medical College
of Georgia, Augusta, GA). Knockout DME, Knockout serum replacement,
ES qualified FBS, N2 supplement, and FGF-2 were obtained from Invitro-
gen/GIBCO BRL. DME/F-12 50/50 mix was purchased from Cellgro.
Nonenzymatic cell dissociation solution, Hoechst 33258, myriocin, poly-
clonal antivimentin goat antiserum, and goat anti–rabbit IgG HRP conjugate
were obtained from Sigma-Aldrich. Myristoylated PKC  pseudosubstrate in-
hibitor peptide was obtained from Calbiochem. N-acetyl sphingosine (C2-
ceramide) and N-palmitoyl sphingosine (C16-ceramide) was obtained from
Matreya. Polyclonal anti–Oct-4 rabbit IgG, polyclonal anti– -fetoprotein
rabbit IgG, polyclonal anti-PAR-4 rabbit IgG, polyclonal anti-PAR-4 goat
IgG, and monoclonal anti-PAR-4 mouse IgG were purchased from Santa
Cruz Biotechnology, Inc. Polyclonal anti-cleaved caspase 3 rabbit IgG
was purchased from Cell Signaling Technologies. Anti-mouse nestin mouse
monoclonal IgG (clone Rat 401), anti-desmin mouse monoclonal IgG (clone
RD 301), and anti-Bcl-2 monoclonal mouse IgG (clone 7) were obtained
from BD Biosciences. Polyclonal anti–  galactosidase rabbit IgG was ob-
tained from Abcam and monoclonal anti–  galactosidase mouse IgG (clone
40-1a) was obtained from the Developmental Studies Hybridoma Bank.
Donkey anti–mouse, –rabbit, and –goat IgG Cy2, Cy3, and Cy5 conju-
gates, goat anti–mouse IgG HRP conjugate, and normal donkey serum
were purchased from Jackson ImmunoResearch Laboratories. Monoclonal
anti–  tubulin III mouse IgG (clone TU-20), mouse anti–human nestin mono-
clonal IgG (clone 10C2), ESGRO (LIF), and the pan-caspase FLICA assay kit
were obtained from Chemicon. The in situ TUNEL fluorescence staining kit
was purchased from Oncogene Research Products, and the mouse chromo-
some Y FISH kit was obtained from Cambio. Alexa 488–conjugated An-
nexin V and Vybrant CM diI and diO were obtained from Molecular
Probes. The MACS kit including Annexin V–conjugated magnetic beads
was purchased from Miltenyi Biotec. All reagents were of analytical grade
or higher and solvents were freshly redistilled before use.
Methods
ES cell differentiation, apoptosis induction, and MACS. In vitro neural dif-
ferentiation of mouse and human ES cells (ES-J1, ROSA 26) followed a se-
rum deprivation protocol as described previously (Okabe et al., 1996;
Hancock et al., 2000; Bieberich et al., 2003). For MACS, cells were dis-
sociated by incubation with trypsin, washed with PBS, and incubated for
20 min at 4 C with Annexin V–conjugated magnetic beads. Annexin
V–negative (flow through) and –positive (retained cells) fractions were col-
lected by passage through a MACS column following the manufacturer’s
(Miltenyi Biotec) procedures.
Transplantation of mouse EBCs. The ceramide analogue-treated or
untreated mouse EBs were nonenzymatically dissociated and labeled with
Vybrant CM diI or diO according to the manufacturer’s protocol (Molecu-
lar Probes). The dissociated EBCs were used for in vitro neural differentia-
tion or transplantation into the striatum of 10-d-old C57CLB6 mice by in-
tracranial injection (bregma  1 mm, right hemisphere 2 mm off suture, 2
mm deep) of 10
5 EBCs in 5  l of 0.9% sterile saline solution (Yanai et al.,
1995). We transplanted equal numbers of viable untreated and S18-
treated cells as determined by trypan blue staining.
Immunostaining, Y-FISH, and apoptosis assays. Differentiating ES
cells (EBs and EBCs) on poly-L-ornithine/laminin-coated coverslips or fro-
zen brain sections were fixed with 4% PFA in PBS and then permeabilized
by incubation with 0.2% Triton X-100 in PBS for 5 min at RT. TUNEL as-
says were performed before immunostaining according to a protocol pro-
vided by the supplier (Oncogene Research Products). FLICA assays for ac-
tive caspases were performed with living cells before fixation following the
manufacturer’s protocol (Chemicon). The immunostaining of fixed cells or
brain sections followed procedures described previously using a blocking
solution of 3% ovalbumin/2% donkey serum in PBS and concentrations of
5  g/ml primary or secondary antibody in 0.1% ovalbumin/PBS (Bieber-
ich et al., 2000, 2002). Y-chromosome FISH was performed according to
the supplier’s instructions (Cambio) after the brain sections were immu-
nostained and underwent a second round of fixation with 4% PFA in PBS.
Cell nuclei were stained with 2  g/ml of Hoechst 33258 in PBS for 30
min at RT. Antigen specific immunostaining was quantified by counting
cells that showed signals twofold or more above background fluorescence
and the cell counts statistically evaluated using ANOVA and a Chi Square
test as described previously (Bieberich et al., 2003). Epifluorescence mi-
croscopy was performed with a microscope (model Axiophot; Carl Zeiss
MicroImaging, Inc.) using 40  (NA 1.0, oil, plan-apochromat) and 100 
(NA 1.4, oil, plan-apochromat) objectives and a Spot II CCD camera.
Confocal fluorescence microscopy was performed with a confocal scan-
ning microscope (model LSM 510; Carl Zeiss MicroImaging, Inc.;
equipped with Argon-488 and He-Neon 543, 633 lasers) using 40  (NA
1.3, oil, plan-neofluor) and 63  (NA 1.4, oil, apochromat) objectives.
Fluorochromes are listed in Materials and methods and the legends for the
figures. Spot Software (Scientific Diagnostics) and LSM 510 Meta 3.2 soft-
ware (Carl Zeiss MicroImaging, Inc.) was used for image acquisition from
epifluorescence or confocal microscopy, respectively. Adobe Photoshop
7.0 software was used for background reduction, pseudo-colorizing, and
overlaying of pseudo-colorized grayscale images.
RT-PCR. Total RNA was prepared from ceramide analogue-treated
or untreated EBCs using the Trizol method following the manufacturer’s
(Life Systems) protocol. PCR was performed by applying 35 cycles with
various amounts of first strand cDNA template (equivalent to 0.05–0.2  g
of RNA) and 20 pmoles of sense and antisense oligonucleotide primer.
The following oligonucleotide primer sequences and annealing tempera-
tures were used: PAR-4 (sense, 5 ccagcgccaggaaaggcaaag3 ; antisense,
5 ctaccttgtcagctgcccaacaac3 ; 61 C), Oct-4 (sense, 5 ggagaggtgaaa-
ccgtccctagg3 ; antisense, 5 agaggaggttccctctgagttgc3 ; 61 C); Tert (sense,
5 ctgcgtgtgcgtgctctggac3 ; antisense, 5 gacctcagcaaacagcttgttctc, 60 C);
Sox-2 (sense, 5 gtggaaacttttgtccgagac3 ; antisense, 5 tggagtgggaggaag-
aggtaac3 , 53 C); Sox-1 (sense, 5 ctgctcaagaaggacaagta3 ; antisense,
5 ctcatgtagccctgagagt3 , 52 C); NF-66 (sense, 5 gcacgtaccattgagataga3 ,
antisense, 5 ctggtactttcttctgtagc3  52 C); GAPDH (sense, 5 gaaggtgaa-
ggtcggagtcaacg3 ; antisense, 5 ggtgatgggatttccattgatgacaagc3 ; 58 C).
The amount of template from each sample was adjusted until PCR yielded
equal intensities of amplification product using GAPDH-specific primers.
Miscellaneous. The amount of protein was determined following
a modified Folin phenol reagent (Lowry) assay as described previously
(Wang and Smith, 1975). Protein extracted with detergent was precipitated
according to the Wessel and Flugge method (Wessel and Flugge, 1984).
SDS-PAGE was performed using the Laemmli method followed by immuno-
blotting as described previously (Laemmli, 1970). Coimmunoprecipitation
assays were performed as described previously (Wang et al., 1999).
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